文献速递前列腺癌

MyProstateScore尿液检测对前列腺穿刺决策的影响:当代学术实践结果

Impact of the MyProstateScore (MPS) Test on the Clinical Decision to Undergo Prostate Biopsy: Results From a Contemporary Academic Practice.
PubMed 文献 · Urology · 2020-08-08

本研究评估了MyProstateScore(MPS)尿液检测对因前列腺穿刺转诊男性穿刺决策的影响。MPS作为立即穿刺的替代方案提供,主要终点是穿刺决策。248例中134例(54%)进行了穿刺,MPS与穿刺决策强烈相关,且经mpMRI分层后仍持续。

要点

  • MPS检测可作为立即前列腺穿刺的替代方案,46%患者避免穿刺。
  • MPS与穿刺决策强烈相关,穿刺率随MPS五分位升高而增加。
  • MPS与穿刺决策的关联在mpMRI分层后仍持续存在。

核心结论

  • 许多接受临床MPS检测作为立即前列腺穿刺替代方案的患者(46%)能够避免穿刺。
  • MPS升高与穿刺率强烈相关,且这些发现在使用mpMRI后仍稳健。

研究设计与样本

  • 共248例患者,主要终点为进行穿刺的决策,并将穿刺比例与前列腺癌预防试验风险计算器(PCPTrc)预测风险评分进行比较。
  • 分析按多参数磁共振成像(mpMRI)使用情况分层,并在多变量逻辑回归模型中探索PCPTrc、MPS和mpMRI与穿刺决策的关联。

主要发现

  • 248例患者中134例(54%)进行了前列腺穿刺。
  • 穿刺患者的MPS显著更高(中位数29 vs 14,P < .001)。
  • 穿刺率随MPS五分位增加而升高:第一至第五分位分别为26%、38%、58%、90%和85%(P < .001)。
  • 经mpMRI分层后,MPS与穿刺的关联持续存在。
  • 多变量分析中,MPS作为连续变量(OR 1.05,95% CI 1.04-1.08,P < .001)和二分变量(OR 7.76,95% CI 4.14-14.5,P < .001)均与穿刺决策强烈相关。

临床怎么用

  • 在临床决策中,MPS检测可作为立即前列腺穿刺的替代方案,帮助部分患者避免不必要的穿刺。
  • MPS结果可与mpMRI结合使用,以辅助前列腺穿刺决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the association of the MyProstateScore (MPS) urine test on the decision to undergo biopsy in men referred for prostate biopsy in urology practice. METHODS: MPS testing was offered as an alternative to immediate biopsy in men referred to the University of Michigan for prostate biopsy from October 2013 through October 2016. The primary endpoint was the decision to perform biopsy. The proportion of patients undergoing biopsy was compared to predicted risk scores from the Prostate Cancer Prevention Trial risk calculator (PCPTrc). Analyses were stratified by the use of multiparametric magnetic resonance imaging (mpMRI). The associations of PCPTrc, MPS, and mpMRI with the decision to undergo biopsy were explored in a multivariable logistic regression model. RESULTS: Of 248 patients, 134 (54%) proceeded to prostate biopsy. MPS was significantly higher in biopsied patients (median 29 vs14, P < .001). The use of biopsy was strongly associated with MPS, with biopsy rates of 26%, 38%, 58%, 90%, and 85% in the first through fifth quintiles, respectively (P < .001). MPS association with biopsy persisted upon stratification by mpMRI. On multivariable analysis, MPS was strongly associated with the decision to undergo biopsy when modeled as both a continuous (odds ratio [OR] 1.05, 95%; confidence interval [CI] 1.04-1.08; <.001) and binary (OR 7.76, 95%; CI 4.14-14.5; P < .001) variable. CONCLUSION: Many patients (46%) undergoing clinical MPS testing as an alternative to immediate prostate biopsy were able to avoid biopsy. Increasing MPS was strongly associated with biopsy rates. These findings were robust to use of mpMRI.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Lebastchi AH, Russell CM, Niknafs YS, et al. Impact of the MyProstateScore (MPS) Test on the Clinical Decision to Undergo Prostate Biopsy: Results From a Contemporary Academic Practice. Urology. 2020. PMID: 32777370. doi:10.1016/j.urology.2020.07.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。